{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:08:10Z","timestamp":1782151690958,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10067-020-05399-4","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T19:08:46Z","timestamp":1600715326000},"page":"2457-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders"],"prefix":"10.1007","volume":"40","author":[{"given":"Saion","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2364","authenticated-orcid":false,"given":"John D.","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"21","key":"5399_CR1","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378(21):2010\u20132021. https:\/\/doi.org\/10.1056\/NEJMra1705454","journal-title":"N Engl J Med"},{"issue":"2","key":"5399_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2018-213846","volume":"78","author":"I Uthman","year":"2019","unstructured":"Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M (2019) Management of antiphospholipid syndrome. Ann Rheum Dis 78(2):155\u2013161. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213846","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5399_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, Groot PGDE, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"5399_CR4","first-page":"621","volume":"31","author":"CL Conley","year":"1952","unstructured":"Conley CL (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31:621\u2013622","journal-title":"J Clin Invest"},{"issue":"6398","key":"5399_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/bmj.287.6398.1021","volume":"287","author":"ML Boey","year":"1983","unstructured":"Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR (1983) Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 287(6398):1021\u20131023. https:\/\/doi.org\/10.1136\/bmj.287.6398.1021","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"suppl_1","key":"5399_CR6","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/rheumatology\/kew401","volume":"56","author":"B Thong","year":"2017","unstructured":"Thong B, Olsen NJ (2017) Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford, England) 56(suppl_1):i3\u2013i13. https:\/\/doi.org\/10.1093\/rheumatology\/kew401","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10103","key":"5399_CR7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet (London, England) 390(10103):1685\u20131699. https:\/\/doi.org\/10.1016\/s0140-6736(17)30933-9","journal-title":"Lancet (London, England)"},{"issue":"Suppl 3","key":"5399_CR8","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/rheumatology\/kep105","volume":"48","author":"V Steen","year":"2009","unstructured":"Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford, England) 48(Suppl 3):iii19\u2013iii24. https:\/\/doi.org\/10.1093\/rheumatology\/kep105","journal-title":"Rheumatology (Oxford, England)"},{"issue":"4","key":"5399_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","volume":"16","author":"M Hughes","year":"2020","unstructured":"Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M (2020) Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 16(4):208\u2013221. https:\/\/doi.org\/10.1038\/s41584-020-0386-4","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"5399_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.semarthrit.2018.02.005","volume":"48","author":"D Paxton","year":"2018","unstructured":"Paxton D, Pauling JD (2018) Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review. Semin Arthritis Rheum 48(3):482\u2013494. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.005","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5399_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/acr.23729","volume":"71","author":"JD Pauling","year":"2019","unstructured":"Pauling JD, Reilly E, Smith T, Frech TM (2019) Evolving symptom characteristics of Raynaud's phenomenon in systemic sclerosis and their association with physician and patient-reported assessments of disease severity. Arthritis Care Res 71(8):1119\u20131126. https:\/\/doi.org\/10.1002\/acr.23729","journal-title":"Arthritis Care Res"},{"issue":"1","key":"5399_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jmv.2009.11.001","volume":"35","author":"M Abdallah","year":"2010","unstructured":"Abdallah M, Hamzaoui S, Larbi T, Bouslama K, Harmel A, Ennafaa M, Bahloul Z, Rokbani L, Othmani S, Ben Dridi M, M\u2019Rad S (2010) Etiological profile of digital necrosis of the upper limbs: analysis of 25 cases. J Mal Vasc 35(1):12\u201316. https:\/\/doi.org\/10.1016\/j.jmv.2009.11.001","journal-title":"J Mal Vasc"},{"issue":"1","key":"5399_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2133.2007.08309.x","volume":"158","author":"I Marie","year":"2008","unstructured":"Marie I, Jouen F, Hellot MF, Levesque H (2008) Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158(1):141\u2013144. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08309.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"5399_CR14","doi-asserted-by":"publisher","first-page":"e001012","DOI":"10.1136\/rmdopen-2019-001012","volume":"5","author":"M Martin","year":"2019","unstructured":"Martin M, Martinez C, Arnaud L, Weber JC, Poindron V, Blaison G, Kieffer P, Bonnotte B, Berthier S, Wahl D, Maurier F, Pennaforte JL, Bielefeld P, Magy-Bertrand N, Devilliers H, Martin T (2019) Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis. RMD Open 5(2):e001012. https:\/\/doi.org\/10.1136\/rmdopen-2019-001012","journal-title":"RMD Open"},{"key":"5399_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3389\/fimmu.2018.02457","volume":"9","author":"V Sobanski","year":"2018","unstructured":"Sobanski V, Lemaire-Olivier A, Giovannelli J, Dauchet L, Simon M, Lopez B, Yelnik C, Lambert M, Hatron PY, Hachulla E, Dubucquoi S, Launay D (2018) Prevalence and clinical associations of antiphospholipid antibodies in systemic sclerosis: new data from a French cross-sectional study, systematic review, and meta-analysis. Front Immunol 9:2457. https:\/\/doi.org\/10.3389\/fimmu.2018.02457","journal-title":"Front Immunol"},{"issue":"12","key":"5399_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1136\/ard.2005.038430","volume":"64","author":"G Sanna","year":"2005","unstructured":"Sanna G, Bertolaccini ML, Mameli A, Hughes GR, Khamashta MA, Mathieu A (2005) Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann Rheum Dis 64(12):1795\u20131796. https:\/\/doi.org\/10.1136\/ard.2005.038430","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5399_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08916939508993333","volume":"20","author":"U Picillo","year":"1995","unstructured":"Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G (1995) Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 20(1):1\u20137. https:\/\/doi.org\/10.3109\/08916939508993333","journal-title":"Autoimmunity"},{"issue":"1","key":"5399_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4274\/tjh.2012.0059","volume":"30","author":"AO Tour\u00e9","year":"2013","unstructured":"Tour\u00e9 AO, Ly F, Sall A, Diatta A, Gadji M, Seck M, Faye B, Dieye T, Diop S (2013) Antiphospholipid antibodies and systemic scleroderma. Turk J Haematol 30(1):32\u201336. https:\/\/doi.org\/10.4274\/tjh.2012.0059","journal-title":"Turk J Haematol"},{"issue":"3","key":"5399_CR19","first-page":"456","volume":"73","author":"RG Malia","year":"1988","unstructured":"Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR, Moult J, Holt CM, Lindsey N, Hughes P (1988) Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 73(3):456\u2013460","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"5399_CR20","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/art.24684","volume":"60","author":"F Boin","year":"2009","unstructured":"Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L (2009) Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 60(8):2480\u20132489. https:\/\/doi.org\/10.1002\/art.24684","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5399_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019\u20131027. https:\/\/doi.org\/10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5399_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/0961203309106832","volume":"18","author":"R Cervera","year":"2009","unstructured":"Cervera R, Boffa MC, Khamashta MA, Hughes GR (2009) The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 18(10):889\u2013893. https:\/\/doi.org\/10.1177\/0961203309106832","journal-title":"Lupus"},{"issue":"2-3","key":"5399_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12016-008-8108-8","volume":"36","author":"L Stojanovich","year":"2009","unstructured":"Stojanovich L, Marisavljevic D, Rovensky J, Djokovich A, Kozakova D, Milinic N (2009) Clinical and laboratory features of the catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol 36(2-3):74\u201379. https:\/\/doi.org\/10.1007\/s12016-008-8108-8","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"5399_CR24","first-page":"46","volume":"75","author":"TM Reshetniak","year":"2003","unstructured":"Reshetniak TM, Alekberova ZS, Kotel'nikova GP, Aleksandrova EN, Mach ES, Radenska-Lopovok SG, Kalashnikova LA, Nasonova VA (2003) Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up. Ter Arkh 75(5):46\u201351","journal-title":"Ter Arkh"},{"issue":"1","key":"5399_CR25","first-page":"22","volume":"19","author":"N Cailleux","year":"1994","unstructured":"Cailleux N, Levesque H, Gilbert P, Joly P, Lauret P, Testart J, Watelet J, Courtois H (1994) Digital necrosis of the arm excluding scleroderma. Retrospective study of 45 cases. J Mal Vasc 19(1):22\u201326","journal-title":"J Mal Vasc"},{"key":"5399_CR26","doi-asserted-by":"publisher","first-page":"w13159","DOI":"10.4414\/smw.2011.13159","volume":"141","author":"HH Keo","year":"2011","unstructured":"Keo HH, Umer M, Baumgartner I, Willenberg T, Gretener SB (2011) Long-term clinical outcomes in patients diagnosed with severe digital ischemia. Swiss Med Wkly 141:w13159. https:\/\/doi.org\/10.4414\/smw.2011.13159","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"5399_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.annder.2015.02.018","volume":"142","author":"A Marchal","year":"2015","unstructured":"Marchal A, Mahe E, Sin C, Bagan P, Bilan P, Linder JF, Couffinhal JC, Sigal ML (2015) Acute finger ischemia: a retrospective study of 13 patients. Ann Dermatol Venereol 142(5):332\u2013339. https:\/\/doi.org\/10.1016\/j.annder.2015.02.018","journal-title":"Ann Dermatol Venereol"},{"issue":"10","key":"5399_CR28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, D\u00f6rner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296\u20131304. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5399_CR29","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1016\/s2352-3026(16)30079-5","volume":"3","author":"H Cohen","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Dore CJ, Khamashta M, Isenberg DA (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematol 3(9):e426\u2013e436. https:\/\/doi.org\/10.1016\/s2352-3026(16)30079-5","journal-title":"Lancet Haematol"},{"issue":"13","key":"5399_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"issue":"5","key":"5399_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/ard.48.5.362","volume":"48","author":"CG Mackworth-Young","year":"1989","unstructured":"Mackworth-Young CG, Loizou S, Walport MJ (1989) Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 48(5):362\u2013367. https:\/\/doi.org\/10.1136\/ard.48.5.362","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5399_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/0961203315622898","volume":"25","author":"S Cekic","year":"2016","unstructured":"Cekic S, Kilic SS (2016) Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon. Lupus 25(5):558\u2013560. https:\/\/doi.org\/10.1177\/0961203315622898","journal-title":"Lupus"},{"issue":"1","key":"5399_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1538574418791355","volume":"53","author":"Y Kadoya","year":"2019","unstructured":"Kadoya Y, Zen K, Oda Y, Matoba S (2019) Successful endovascular treatment for aortic thrombosis due to primary antiphospholipid syndrome: a case report and literature review. Vasc Endovasc Surg 53(1):51\u201357. https:\/\/doi.org\/10.1177\/1538574418791355","journal-title":"Vasc Endovasc Surg"},{"issue":"3","key":"5399_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/s0022-3476(96)70064-1","volume":"129","author":"E von Scheven","year":"1996","unstructured":"von Scheven E, Athreya BH, Rose CD, Goldsmith DP, Morton L (1996) Clinical characteristics of antiphospholipid antibody syndrome in children. J Pediatr 129(3):339\u2013345. https:\/\/doi.org\/10.1016\/s0022-3476(96)70064-1","journal-title":"J Pediatr"},{"issue":"36","key":"5399_CR35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1055\/s-2003-41967","volume":"128","author":"F Stammler","year":"2003","unstructured":"Stammler F, Lawall H, Diehm C (2003) Repeated attacks of pain in the nipple of a pregnant woman. Unusual manifestation of Raynaud's phenomenon. Dtsch Med Wochenschr (1946) 128(36):1825\u20131828. https:\/\/doi.org\/10.1055\/s-2003-41967","journal-title":"Dtsch Med Wochenschr (1946)"},{"issue":"4","key":"5399_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1191\/0961203306lu2268cr","volume":"15","author":"F Ingegnoli","year":"2006","unstructured":"Ingegnoli F, Soldi A, Meani L, Zeni S, Fantini F (2006) Primary antiphospholipid syndrome associated with small aorta syndrome: a case report. Lupus 15(4):236\u2013239. https:\/\/doi.org\/10.1191\/0961203306lu2268cr","journal-title":"Lupus"},{"issue":"3","key":"5399_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.7547\/17-108","volume":"109","author":"DG Dimond","year":"2019","unstructured":"Dimond DG, Lam JK, Wurster L, Kiser C, Driscoll K, Razzante M (2019) The solitary blue toe: a unique presentation of antiphospholipid syndrome. J Am Podiatr Med Assoc 109(3):235\u2013240. https:\/\/doi.org\/10.7547\/17-108","journal-title":"J Am Podiatr Med Assoc"},{"issue":"2","key":"5399_CR38","doi-asserted-by":"publisher","first-page":"e232907","DOI":"10.1136\/bcr-2019-232907","volume":"13","author":"S Cheemalavagu","year":"2020","unstructured":"Cheemalavagu S, McCoy SS, Knight JS (2020) Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. BMJ Case Rep 13(2):e232907. https:\/\/doi.org\/10.1136\/bcr-2019-232907","journal-title":"BMJ Case Rep"},{"issue":"769","key":"5399_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/pgmj.65.769.837","volume":"65","author":"SW Roche","year":"1989","unstructured":"Roche SW, Niriella DC, O'Mahoney A, Cayley AC (1989) The anti-phospholipid antibody syndrome in a 77 year old man with digital gangrene. Postgrad Med J 65(769):837\u2013839. https:\/\/doi.org\/10.1136\/pgmj.65.769.837","journal-title":"Postgrad Med J"},{"issue":"2","key":"5399_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2133.2007.07989.x","volume":"157","author":"K Eisendle","year":"2007","unstructured":"Eisendle K, Jaschke W, Sepp N (2007) Livedo racemosa and digital necrosis in a patient with primary seronegative antiphospholipid syndrome and fibromuscular dysplasia of peripheral arteries. Br J Dermatol 157(2):389\u2013392. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07989.x","journal-title":"Br J Dermatol"},{"key":"5399_CR41","doi-asserted-by":"publisher","first-page":"bcr2012006731","DOI":"10.1136\/bcr-2012-006731","volume":"2012","author":"CR Crome","year":"2012","unstructured":"Crome CR, Rajagopalan S, Kuhan G, Fluck N (2012) Antiphospholipid syndrome presenting with acute digital ischaemia, avascular necrosis of the femoral head and superior mesenteric artery thrombus. BMJ Case Rep 2012:bcr2012006731. https:\/\/doi.org\/10.1136\/bcr-2012-006731","journal-title":"BMJ Case Rep"},{"issue":"5","key":"5399_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11739-015-1335-0","volume":"11","author":"JA Vargas-Hitos","year":"2016","unstructured":"Vargas-Hitos JA, Sabio JM, Navarrete-Navarrete N, Zamora-Pasadas M, Jimenez-Alonso J (2016) Severe digital necrosis as the clinical onset of antiphospholipid syndrome. Intern Emerg Med 11(5):761\u2013762. https:\/\/doi.org\/10.1007\/s11739-015-1335-0","journal-title":"Intern Emerg Med"},{"issue":"5","key":"5399_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.semarthrit.2016.10.004","volume":"46","author":"M Merashli","year":"2017","unstructured":"Merashli M, Alves J, Ames PRJ (2017) Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis. Semin Arthritis Rheum 46(5):615\u2013624. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.004","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"5399_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/09537104.2012.719090","volume":"24","author":"JD Pauling","year":"2013","unstructured":"Pauling JD, O\u2019Donnell VB, McHugh NJ (2013) The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis. Platelets 24(7):503\u2013515. https:\/\/doi.org\/10.3109\/09537104.2012.719090","journal-title":"Platelets"},{"issue":"8","key":"5399_CR45","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, M\u00fcller-Ladner U (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5399_CR46","first-page":"499","volume":"18","author":"CP Denton","year":"2000","unstructured":"Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 18(4):499\u2013502","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"5399_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMra1112830","volume":"368","author":"B Giannakopoulos","year":"2013","unstructured":"Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033\u20131044. https:\/\/doi.org\/10.1056\/NEJMra1112830","journal-title":"N Engl J Med"},{"issue":"6","key":"5399_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","volume":"7","author":"PL Meroni","year":"2011","unstructured":"Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7(6):330\u2013339. https:\/\/doi.org\/10.1038\/nrrheum.2011.52","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"5399_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1067\/mjd.2000.107499","volume":"43","author":"EM Sachsenberg-Studer","year":"2000","unstructured":"Sachsenberg-Studer EM, Prins C, Saurat JH, Salomon D (2000) Raynaud's phenomenon, anticentromere antibodies, and digital necrosis without sclerodactyly: an entity independent of scleroderma? J Am Acad Dermatol 43(4):631\u2013634. https:\/\/doi.org\/10.1067\/mjd.2000.107499","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5399_CR50","first-page":"875","volume":"15","author":"WG Barr","year":"1988","unstructured":"Barr WG, Robinson JA (1988) Systemic sclerosis and digital gangrene without scleroderma. J Rheumatol 15(5):875\u2013877","journal-title":"J Rheumatol"},{"issue":"8","key":"5399_CR51","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/36.8.889","volume":"36","author":"M Takahashi","year":"1997","unstructured":"Takahashi M, Okada J, Kondo H (1997) Six cases positive for anti-centromere antibodies with ulcer and gangrene in the extremities. Br J Rheumatol 36(8):889\u2013893. https:\/\/doi.org\/10.1093\/rheumatology\/36.8.889","journal-title":"Br J Rheumatol"},{"key":"5399_CR52","doi-asserted-by":"publisher","unstructured":"Bandettini di Poggio M, Murdaca G, Puppo F, Primavera A (2010) Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. Semin Arthritis Rheum 40(3):e9\u2013e10. https:\/\/doi.org\/10.1016\/j.semarthrit.2009.08.004","DOI":"10.1016\/j.semarthrit.2009.08.004"},{"key":"5399_CR53","doi-asserted-by":"publisher","first-page":"7438676","DOI":"10.1155\/2018\/7438676","volume":"2018","author":"H Hirashima","year":"2018","unstructured":"Hirashima H, Iwamoto M, Ozawa T, Kijima S, Matsubara S, Ohkuchi A (2018) Posterior Reversible Encephalopathy Syndrome with Stroke in Puerperal Woman with High Titer of Anti-Phospholipid IgM Antibody. Case Rep Obstet Gynecol 2018:7438676\u20137438675. https:\/\/doi.org\/10.1155\/2018\/7438676","journal-title":"Case Rep Obstet Gynecol"},{"issue":"1","key":"5399_CR54","first-page":"76","volume":"28","author":"T Parikh","year":"2007","unstructured":"Parikh T, Shifteh K, Lipton ML, Bello JA, Brook AL (2007) Deep brain reversible encephalopathy: association with secondary antiphospholipid antibody syndrome. AJNR Am J Neuroradiol 28(1):76\u201378","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"5399_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000103618","volume":"24","author":"D Renard","year":"2007","unstructured":"Renard D, Dutray A, Le Quellec A, Milhaud D (2007) Reversible posterior leukoencephalopathy syndrome in catastrophic antiphospholipid syndrome. Cerebrovasc Dis (Basel, Switzerland) 24(1):141\u2013143. https:\/\/doi.org\/10.1159\/000103618","journal-title":"Cerebrovasc Dis (Basel, Switzerland)"},{"issue":"8","key":"5399_CR56","first-page":"1455","volume":"22","author":"JM Provenzale","year":"2001","unstructured":"Provenzale JM, Petrella JR, Cruz LC Jr, Wong JC, Engelter S, Barboriak DP (2001) Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 22(8):1455\u20131461","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05399-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05399-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05399-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T01:23:38Z","timestamp":1632187418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05399-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5399"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05399-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Saion Chatterjee does not report any conflicts of interest. John Pauling has received speaker\u2019s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals. John Pauling has undertaken consultancy work for Actelion pharmaceuticals, Sojournix Pharma and Boehringer Ingelheim, outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained to present medical images and provide details of the medical history from each patient included in this case-based review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}